Table 3.
Multivariate Survival Analysis in Patients with ESCC
| Characteristics | Progression-Free Survival | Overall Survival | ||
|---|---|---|---|---|
| HR (95% CI) | p-value | HR (95% CI) | p-value | |
| Male | 1.12 (0.81–1.53) | 0.498 | 0.89 (0.63–1.26) | 0.522 |
| Tumor length ≥ 5.5 (cm) | 1.45 (1.12–1.88) | 0.005 | 0.98 (0.74–1.29) | 0.879 |
| Current and former smoker | 1.40 (1.06–1.84) | 0.017 | 1.43 (1.07–1.91) | 0.015 |
| Alcoholic | 1.29 (0.97–1.71) | 0.081 | 1.20 (0.89–1.61) | 0.237 |
| ECOG performance status (vs 0) | < 0.001 | < 0.001 | ||
| 1 | 1.79 (1.32–2.43) | 2.01 (1.45–2.80) | ||
| 2 | 3.37 (2.19–5.21) | 4.71 (2.95–7.51) | ||
| Invasion depth (vs pT1) | 0.145 | 0.041 | ||
| pT2 | 1.46 (0.86–2.50) | 1.72 (0.91–3.23) | ||
| pT3 | 1.80 (1.06–3.05) | 2.33 (1.28–4.27) | ||
| pT4 | 2.02 (0.92–4.44) | 2.31 (0.98–5.46) | ||
| Lymph node metastasis (vs pN0) | 0.002 | 0.038 | ||
| pN1 | 1.40 (0.88–2.21) | 1.20 (0.72–1.98) | ||
| pN2 | 2.25 (1.41–3.59) | 1.82 (1.10–3.01) | ||
| pN3 | 2.24 (1.00–4.99) | 1.92 (0.80–4.61) | ||
| Tumor location (vs Upper thoracic) | 0.102 | 0.065 | ||
| Midthoracic | 1.21 (0.91–1.61) | 1.27 (0.94–1.73) | ||
| Lower thoracic | 1.48 (1.03–2.12) | 0.84 (0.56–1.25) | ||
| Pathological complete response (vs Others) | 0.74 (0.47–1.34) | 0.134 | 0.83 (0.58–1.32) | 0.192 |
| Pretreatment NLR ≥ 2.77 | 0.96 (0.69–1.33) | 0.796 | 1.02 (0.70–1.48) | 0.930 |
| Pretreatment PLR ≥ 142.17 | 1.59 (1.15–2.21) | 0.005 | 1.74 (1.24–2.46) | 0.002 |
| Pretreatment SII ≥ 583.45 | 2.14 (1.45–3.15) | < 0.001 | 2.95 (1.92–4.54) | < 0.001 |
| AFR ≥ 10.36 | 1.14 (0.88–1.47) | 0.338 | 0.88 (0.67–1.16) | 0.363 |
Abbreviations: ESCC, esophageal squamous cell carcinoma; HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; NLR, neutrophil to lymphocyte ratio; PLR, platelet to lymphocyte ratio; SII, systemic immune-inflammation index; AFR, albumin to fibrinogen ratio.